Enzyme Inhibitor Antibiotics and Antibiotic-Associated Diarrhea in Critically Ill Patients

Yanshu Zhang
Jingjing Sun
Jing Zhang
Yu Liu
Litao Guo

Corresponding Authors: Yu Liu, e-mail: doctorliuyu@263.net, Litao Guo, e-mail: glt02@163.com

Background: This study aimed to analyze the factors associated with the development of antibiotic-associated diarrhea (AAD) in critically ill patients receiving enzyme inhibitor antibiotics.

Material/Methods: A retrospective study of patients with and without AAD admitted to the intensive care unit (ICU) of the First Teaching Hospital of Xi’an Jiaotong University from February 1, 2014, to January 31, 2016, was undertaken. Relevant clinical data underwent univariate or multivariate regression analysis.

Results: Of 184 patients who received enzyme inhibitor antibiotic therapy, 70 patients (38.04%) developed AAD, with a mean duration of onset of 6.97±3.64 days. AAD was associated with the use of enzyme inhibitor antibiotic therapy alone (OR, 1.142; 95% CI, 1.038–1.256; P=0.007), and in combination with antifungal agents (OR, 2.449; 95% CI, 1.116–5.372; P=0.025), quinolones (OR, 5.219; 95% CI, 1.746–15.601; P=0.003), and oxazolidinones (OR 2.895; 95% CI, 1.183–7.083; P=0.020). The mean duration of ICU stay was significantly increased in patients with AAD (19.00±11.49 days vs. 9.60±6.76 days) (P<0.001). Mean duration of antibiotic therapy (14.09±8.82 days vs. 8.10±4.91 days) (P<0.001) and duration of enzyme inhibitor antibiotic therapy (9.26±5.06 days vs. 6.61±3.24 days) (P<0.001) were significantly increased in patients with AAD.

Conclusions: Duration of use of enzyme inhibitor antibiotic therapy and the combined use of antifungals, quinolones, and oxazolidinones increased the incidence and duration of AAD and increased the length of stay in ICU.

MeSH Keywords: Antifungal Agents • Clostridium Difficile • Diarrhea • Enzyme Inhibitors • Intensive Care Units

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/913739
Background

The extensive use of antibiotics has led to the increased annual incidence of antibiotic-associated diarrhea (AAD) [1]. AAD is a syndrome resulting from changes in intestinal flora associated with disorders of varying severity caused by antibiotic treatment, with the primary symptom being diarrhea [1]. The reported incidence of AAD in patients treated with antibiotics varies from between 5–35% [1–3], possibly due to differences in the populations studied and the types of antibiotics used. The prevalence of AAD increases in cases of combined antibiotic treatment. AAD can occur within several hours after the start of antibiotic therapy and can also occur at up to 6–8 weeks after the antibiotic therapy has been discontinued. A delay in diagnosis can lead to serious complications and, mortality rates as that have been reported to be as high as 15–24% [4].

AAD is predominantly caused by Clostridium difficile, Klebsiella sp., and Staphylococcus aureus, as well as some fungi and viruses. C. difficile is the most common pathogen causing AAD [3,5,6]. The recent increase in the incidence of AAD has made C. difficile an important nosocomial infection, particularly in hospitalized patients. Therefore, AAD increases patient morbidity and mortality, the length of hospital stay, and healthcare costs [7–9]. In patients admitted to the intensive care unit (ICU), the incidence of AAD is considerably increased, and the condition is more severe [1]. Therefore, AAD is a condition that should be prevented in critically ill patients.

Previously published studies have shown that combined antibiotic treatment, parenteral nutrition, and hospital stay are associated with the occurrence of AAD [1,9,10]. Also, different types of antibiotics have different risks of causing AAD [3]. Some antibiotics inhibit the enzymes that are essential for the growth of pathogens and include commonly used antibiotics such as penicillin and vancomycin, which are more commonly used in critically ill patients because they are effective broad-spectrum antimicrobial [1]. However, enzyme inhibitor antibiotics are also associated with the development of AAD in critically ill patients [1]. A recent study showed that the incidence of AAD was significantly different between patients who treated with enzyme inhibitor antibiotics compared with non-enzyme inhibitor antibiotics (35.36% vs. 21.43%) (P=0.013) [1]. However, the mechanisms associated with the effects of enzyme inhibitor antibiotics and the development of AAD remain unclear. Therefore, this study aimed to analyze the factors associated with the development of AAD in critically ill patients receiving enzyme inhibitor antibiotics.

Material and Methods

Study design

A retrospective study reviewed the medical records of critically ill patients admitted to the intensive care unit (ICU) of the First Affiliated Hospital of Xi’an Jiaotong University between February 1, 2014 and January 31, 2016, who received enzyme inhibitor antibiotic therapy. The patients were divided into the antibiotic-associated diarrhea (AAD) treatment group and non-AAD treatment group. The inclusion criteria were patients admitted to the ICU who had the first use of enzyme inhibitor antibiotic therapy, and treatment that lasted for more than three days [10]. The exclusion criteria included patients who were admitted to the ICU who were not treated with an enzyme inhibitor antibiotic, or multiple admissions to the ICU within one month, or a previous diagnosis of AAD within the preceding three months, and incomplete or missing case file data [1]. All study participants provided informed consent, and this study was reviewed and approved by The First Affiliated Hospital of Xi’an Jiaotong University Ethics Committee (No. XJTU1AF2018LSK-097).

Diagnosis of antibiotic-associated diarrhea (AAD)

Diagnosis of the critically ill patients recruited for this study was made according to the US 2013 guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections [5], and the 2014 European Society of Clinical Microbiology and Infectious Diseases guidance document for the treatment of C. difficile infection [11].

Data collection

Baseline patient clinical and demographic data were collected from the medical records and included data on the presence of diabetes, loss of appetite exceeding 72 hours, a history of gastrointestinal surgery, medical treatment including immunosuppressive therapy, and hormone supplementation. Laboratory findings were noted, including serum albumin levels. For each patient included in the study analysis, the Acute Physiology and Chronic Health Evaluation (APACHE II) score on admission to the ICU were retrospectively collected and analyzed.

Statistical analysis

Statistical analysis was performed using SPSS version 18.0 (IBM Corp, Armonk, NY). Data were expressed as the number of cases and percentages and the chi-squared (χ²) test was used for correlation between groups. Measurement data were expressed as the mean ± standard deviation (SD), with calculation of the odds ratio (OR) and 95% confidence interval (CI). After the data of all groups were tested for homogeneity of variance
and normal distribution, independent sample t-tests were used to calculate the significant difference between groups, and a P-value <0.05 was considered to be statistically significant. Univariate logistic regression analysis was performed for each variable. Each variable with P <0.05 in the univariate analysis was included in the logistic regression model for independent risk factors using multivariate analysis to determine AAD-related factors. The statistical methods of this study were reviewed by Bin Yan from the Clinical Research Center of the First Affiliated Hospital of Xi’an Jiaotong University.

### Results

#### Patient characteristics

Retrospective clinical review identified 184 patients who were admitted to the intensive care unit (ICU) of the First Affiliated Hospital of Xi’an Jiaotong University between February 1, 2014 and January 31, 2016, who received enzyme inhibitor antibiotic therapy, including 114 men and 70 women (mean age, 55.49±20.54 years). The incidence of antibiotic-associated diarrhea (AAD) was 38.04%, which occurred mainly in patients who had used enzyme inhibitor antibiotics for 6.97±3.64 days. The AAD group included 70 patients (48 men and 22 women) (mean age, 61.01±21.65 years). The non-AAD group included 114 patients, (66 men and 48 women) (mean age, 52.10±19.13 years). (Table 1)

The mean age and incidence of hypertension were significantly different between the AAD group and non-AAD group (all P<0.05). There were no significant differences between the two groups in terms of gender, diabetes, loss of appetite exceeding 72 hours, gastrointestinal surgery, treatment with immunosuppressants or hormone supplements, albumin levels, and the Acute Physiology and Chronic Health Evaluation (APACHE II) score on admission to the ICU (P>0.05). The incidence of AAD was significantly increased in patients treated with a combination of enzyme inhibitors and other antibiotics compared with those who received enzyme inhibitor antibiotic monotherapy (51.00% vs. 22.62%) (P<0.001). (Table 1)

#### Correlation between AAD and the use of enzyme inhibitor antibiotics

Of the 184 patients who received enzyme inhibitor antibiotic therapy, 87 patients (47.28%) were treated with piperacillin-tazobactam, and 97 patients (52.72%) were treated with cefoperazone-sulbactam. The incidence of AAD was 34.48%, which was significantly increased in patients treated with piperacillin-tazobactam combined with other antibiotics than in those treated with piperacillin-tazobactam monotherapy (44.68% vs. 22.50%) (P=0.042). The incidence of AAD was 41.24% in those treated with cefoperazone-sulbactam. The incidence of AAD was significantly increased in patients treated with cefoperazone-sulbactam compared with patients treated with cefoperazone-sulbactam monotherapy (56.60% vs. 22.73%) (P=0.001). There was no significant difference in the incidence of AAD between the different types of enzyme inhibitor antibiotics (P=0.365) (Table 2).

### Table 1. The clinic characteristics of the patients.

| Variables | AAD          | No AAD        | P-value |
|-----------|--------------|---------------|---------|
| No. of patients | 70           | 114           |         |
| Age (years)      | 61.01±21.65  | 52.10±19.13   | 0.004   |
| Male: Female      | 48:22        | 66:48         | 0.162   |
| Hypertension (%)  | 29 (41.43%)  | 27 (23.68%)   | 0.014   |
| Diabetes (%)      | 12 (17.14%)  | 12 (10.53%)   | 0.259   |
| Fasting time exceeding 72 hours (%) | 34 (48.57%) | 58 (50.88%) | 0.879 |
| Gastrointestinal surgery (%) | 6 (8.57%) | 5 (4.39%) | 0.338 |
| Immunosuppressants (%) | 3 (4.29%) | 4 (3.51%) | 0.789 |
| Use of hormones (%) | 38 (54.29%) | 57 (50.00%) | 0.649 |
| Albumin levels (g/L) | 30.56±7.00 | 30.83±7.18 | 0.802 |
| APACHE II score at admission into the ICU (points) | 17.64±6.98 | 16.47±6.50 | 0.251 |
| Enzyme inhibitor in combination with other antibiotics (%) | 51 (72.86%) | 49 (42.98%) | <0.001 |

AAD – antibiotic-associate diarrhea; ICU – intensive care unit; APACHE – Acute Physiology and Chronic Health Evaluation.
Correlation between AAD and treatment with enzyme inhibitor antibiotics in combination with other antibiotics

Of the 184 patients who received enzyme inhibitor antibiotic therapy, 100 patients (54.35%) were treated with combined antibiotics. The incidence of AAD was significantly increased in patients treated with enzyme inhibitor antibiotics combined with oxazolidinones compared with patients treated with enzyme inhibitor antibiotics alone (P=0.001). The incidence of AAD was significantly increased in patients treated with enzyme inhibitor antibiotics combined antifungal agents (P<0.001), with enzyme inhibitor antibiotics combined with carbapenems (P=0.015), and with enzyme inhibitor antibiotics combined with quinolones (P<0.001), compared with patients treated with enzyme inhibitor antibiotics alone (Table 3).

Factors related to AAD in critically ill patients receiving enzyme inhibitor antibiotics

Univariate regression analysis of the risk factors associated with AAD showed that age, use proton pump inhibitors (PPIs), parenteral nutrition, preventive use of probiotics, hypertension, duration of use of enzyme inhibitor antibiotics, antifungal agents, the use of carbapenem, quinolone, and oxazolidinone antibiotics were associated with AAD in critically ill patients receiving enzyme inhibitors antibiotic therapy (Table 4).

Multivariate regression analysis showed that the duration of enzyme inhibitor antibiotic therapy (OR, 1.142; 95% CI, 1.038–1.256; P=0.007) and use of antifungals (OR, 2.449; 95% CI, 1.116–5.372; P=0.025), quinolones (OR, 5.219; 95% CI, 1.746–15.601; P=0.003), and oxazolidinones (OR 2.895; 95% CI, 1.183–7.083; P=0.020) were the risk factors for AAD in critically ill patients receiving enzyme inhibitor antibiotic therapy (Table 4).

Prognostic evaluation

Of the 184 patients who received enzyme inhibitor antibiotic therapy, 20 patients died from their primary disease during the study period, including seven patients in the AAD group and 13 patients in the non-AAD group. The duration of patient stay in the ICU was significantly increased in patients with AAD, compared with patients without AAD (19.00±11.49 days vs. 9.60±6.76 days) (P<0.001). The duration of antibiotic treatment (14.09±8.82 days vs. 8.10±4.91 days) (P<0.001), and duration of enzyme inhibitor antibiotics therapy (9.26±5.06 days vs. 6.61±3.24 days) (P<0.001) were significantly increased in patients with AAD, compared with patients without AAD. There was no significant difference in mortality during the stay in ICU between the two groups (P=0.813), and AAD did not directly cause any deaths in either group (Table 5).

Table 2. Correlation between antibiotic-associated diarrhea (AAD) and enzyme inhibitors.

| Variables | Single antibiotics | Combined antibiotics | P-value | P-value |
|-----------|--------------------|-----------------------|---------|---------|
|           | AAD | No AAD | AAD | No AAD |         |         |
| Piperacillin-tazobactam | 9    | 31    | 21   | 26    | 0.042   | 0.365   |
| Cefoperazone-sulbactam | 10   | 34    | 30   | 23    | 0.001   |         |
| P-value   | 0.98 | 0.316 |       |        |         |         |

Table 3. Correlation between antibiotic-associated diarrhea (AAD) and enzyme inhibitors combined with other antibiotics.

| Variables | AAD | No AAD | P-value |
|-----------|-----|--------|---------|
| No. of patients | 70  | 114    |         |
| Glycopeptides* (%) | 11 (15.71%) | 12 (10.53%) | 0.360  |
| Oxazolidinones** (%) | 25 (35.71%) | 16 (14.04%) | 0.001  |
| Anti-anaerobic bacteria antibiotics* (%) | 10 (14.29%) | 25 (21.93%) | 0.247  |
| Antifungals (%) | 41 (58.57%) | 31 (27.19%) | <0.001 |
| Carbapenems (%) | 25 (35.71%) | 22 (19.30%) | 0.015  |
| Quinolones (%) | 18 (25.71%) | 7 (6.14%)   | <0.001 |
| Azithromycins (%) | 3 (4.29%)  | 11 (9.65%)  | 0.255  |
| Cephalosporins (%) | 13 (18.57%) | 13 (11.40%) | 0.195  |

* Glycopeptides (vancomycin, teicoplanin); ** oxazolidinones (linezolid); # anti-anaerobic bacteria antibiotics were metronidazole.

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
The microflora in the human gastrointestinal tract is not usually associated with disease or abnormalities of function. However, certain antibiotics may disrupt the balance of the normal intestinal microbiota. As a result, antibiotic-sensitive bacteria are eliminated or reduced in number, while drug-resistant bacteria can multiply. For example, *Clostridium difficile* may become the dominant gut bacteria, producing toxins A and B, and cause enteritis and antibiotic-associated diarrhea (AAD) [3,12–14].

### Table 4. Factors related to antibiotic-associated diarrhea (AAD) in critically ill patients receiving enzyme inhibitors.

| Related factors                                 | Univariate regression analysis | Multivariate regression analysis |
|-------------------------------------------------|-------------------------------|---------------------------------|
|                                                 | OR (95% CI)                   | P-value                         | OR (95% CI)                   | P-value                         |
| Age                                             | 1.022 (1.007–1.038)           | 0.005                           | 1.018 (0.999–1.037)           | 0.068                           |
| Gender                                          | 1.587 (0.848–2.970)           | 0.149                           |                                |                                |
| Use of proton pump inhibitors                   | 2.917 (1.188–7.159)           | 0.019                           | 1.922 (0.612–6.035)           | 0.263                           |
| Fasting time exceeding 72 h                     | 1.097 (0.605–1.989)           | 0.761                           |                                |                                |
| Parenteral nutrition                            | 1.951 (1.048–3.632)           | 0.035                           | 1.362 (0.606–3.058)           | 0.454                           |
| Preventive use of probiotics                    | 0.489 (0.263–0.909)           | 0.024                           | 0.892 (0.408–1.952)           | 0.775                           |
| Albumin levels                                  | 1.005 (0.964–1.049)           | 0.801                           |                                |                                |
| Hypertension                                    | 2.279 (1.199–4.332)           | 0.012                           | 1.979 (0.875–4.474)           | 0.101                           |
| Diabetes                                        | 1.759 (0.742–4.167)           | 0.200                           |                                |                                |
| APACHE II score at admission into the ICU       | 1.027 (0.982–1.073)           | 0.250                           |                                |                                |
| Use of hormones                                 | 1.187 (0.654–2.156)           | 0.572                           |                                |                                |
| Duration of enzyme inhibitor antibiotic*        | 1.172 (1.081–1.270)           | <0.001                          | 1.142 (1.038–1.256)           | 0.007                           |
| Antifungals                                     | 3.785 (2.017–7.104)           | <0.001                          | 2.449 (1.116–5.372)           | 0.025                           |
| Cephalosporins                                  | 1.772 (0.769–4.082)           | 0.179                           |                                |                                |
| Carapenems                                      | 2.323 (1.185–4.562)           | 0.014                           | 1.454 (0.601–3.518)           | 0.406                           |
| Quinolones                                      | 5.291 (2.080–13.462)          | <0.001                          | 5.219 (1.746–15.601)          | 0.003                           |
| Glycopeptides**                                 | 1.585 (0.658–3.816)           | 0.304                           |                                |                                |
| Oxazolidinones*                                 | 3.403 (1.656–6.990)           | 0.014                           | 2.895 (1.183–7.083)           | 0.020                           |
| Anti-anaerobic bacteria Antibiotics**           | 0.593 (0.266–1.325)           | 0.203                           |                                |                                |
| Azithromycins                                   | 2.385 (0.642–8.867)           | 0.194                           |                                |                                |

* Enzyme inhibitors were piperacillin-tazobactam and cefoperazone-sulbactam; ** glycopeptides were Vancomycin and teicoplanin; # oxazolidinones was Linezolid; ** anti-anaerobic bacteria antibiotics was metronidazole. AAD – antibiotic-associate diarrhea; ICU – intensive care unit; APACHE – Acute Physiology and Chronic Health Evaluation; OR – odds ratio; CI – confidence interval.

### Table 5. The prognosis of patients with and without antibiotic-associated diarrhea (AAD).

| Variables                          | AAD      | No AAD     | P-value |
|------------------------------------|----------|------------|---------|
| No. of patients                    | 70       | 114        |         |
| ICU stay, days                     | 19.0±11.49 | 9.60±6.76 | <0.001  |
| Duration of antibiotic, days       | 14.09±8.82 | 8.10±4.91 | <0.001  |
| Duration of enzyme inhibitor antibiotic, days | 9.26±5.06 | 6.61±3.24 | <0.001  |
| ICU mortality (%)                  | 7 (10.0%) | 13 (11.4%) | 0.813   |

AAD – antibiotic-associate diarrhea; ICU – intensive care unit.

**Discussion**

The microflora in the human gastrointestinal tract is not usually associated with disease or abnormalities of function. However, certain antibiotics may disrupt the balance of the normal intestinal microbiota. As a result, antibiotic-sensitive bacteria are eliminated or reduced in number, while drug-resistant bacteria can multiply. For example, *Clostridium difficile* may become the dominant gut bacteria, producing toxins A and B, and cause enteritis and antibiotic-associated diarrhea (AAD) [3,12–14].
Because of the recent increased use of antibiotics, AAD has become increasingly common [15,16]. The main clinical manifestations of AAD are diarrhea, mainly presenting with watery stool, sometimes with pus, mucus, or blood, fever, and increased white blood cell count, abdominal distension, abdominal pain, and sometimes more serious associations, including multiple organ dysfunction, and toxic mega colon. A characteristic feature of AAD is the appearance of a large amount of intestinal mucus (pseudomembranous colitis). Among patients with AAD, more than 20% experience initial treatment failure and 40–60% experience a relapse of their symptoms [7,17].

Recent studies have shown that almost all antibiotics can cause AAD [18,19], particularly broad-spectrum antibiotics [20], such as lincomycin, azithromycin, cephalosporin, and penicillin [3,5,21,22]. Also, combined antibiotic treatment is most likely to cause AAD [1]. We previously reported that the incidence of AAD was significantly increased when an enzyme inhibitor antibiotic was used in combination with other antibiotics when compared with enzyme inhibitor antibiotic monotherapy [1]. Subgroup analysis of the type of enzyme inhibitor antibiotics showed that the incidence of AAD was significantly increased in patients treated with enzyme inhibitor antibiotics, regardless of whether it was piperacillin-tazobactam or cefoperazone-sulbactam [1]. The findings of this previously reported study support those of the present study that the incidence of AAD was increased in patients treated with combined antibiotics, with no significant difference in the incidence of AAD between different enzyme inhibitor antibiotics [1].

The findings of the present study showed that the incidence of AAD was significantly increased with the use of enzyme inhibitor antibiotics used in combination with antifungal agents, oxazolidinones, carbapenems, and quinolones. Also, the duration of use of enzyme inhibitor antibiotic therapy and use of antifungals, quinolones, and oxazolidinones and the association with AAD in critically ill patients has not been previously reported [1,10]. The reasons for the increased incidence of AAD in patients treated with enzyme inhibitor antibiotics in combined with antifungal agents may be due to the fact that these patients had more severe disease, reduced immunity, and longer antibiotic use, thus making them vulnerable to developing AAD, and also, the number of patients treated with combined enzyme inhibitor antibiotics and antifungal agents were high in this study population. Further studies with a larger sample size are needed to confirm these findings. However, it is useful to know that for critically ill patients in the intensive care unit (ICU), the use of enzyme inhibitor antibiotics combined with antifungal therapy may increase the risk of AAD.

Treatment with quinolone antibiotics is recognized to be associated with a high risk of the development of drug-resistant bacteria [23]. In particular, combining quinolones with enzyme inhibitor antibiotics has been reported to increase the risk of imbalance in the intestinal flora and increase the risk of AAD, especially in critically ill patients [23]. Studies have also shown that patients treated with cephalosporins are susceptible to AAD [5,22]. However, these previously reported findings were not confirmed in the present study, which may have been due to the relatively small study population. Also, relatively high grades of broad-spectrum antibiotics are selected more often for the patients in the ICU due to their critical condition, while cephalosporins are rarely used in the ICU setting as they are associated with the development of antimicrobial resistant strains of bacteria [24,25].

The findings of the present study showed that the duration of enzyme inhibitor antibiotic therapy was associated with AAD in critically ill patients. Long-term enzyme inhibitor antibiotic therapy may also be related to changes in intestinal flora, resulting in an increased incidence of AAD. In this study, AAD occurred after an average of 6.97±3.64 days following treatment initiation, particularly in patients who were treated with combined antibiotics; the earliest time that AAD developed was after approximately 24 hours from the start of treatment. Despite the development of AAD, these antibiotics cannot be discontinued as they are crucial in the treatment of the patients in the ICU. When patients in ICU with AAD and without AAD were compared, there was a significant difference between the two groups in the duration of antibiotic treatment (14.09±8.82 vs. 8.10±4.91 days) (P<0.001) and the duration of treatment with enzyme inhibitor antibiotics (9.26±5.06 vs. 6.61±3.24 days) (P<0.001). Therefore, clinicians should be made aware of the occurrence of AAD in critically ill patients who require long-term enzyme inhibitor antibiotic therapy.

Treatment with proton pump inhibitors (PPIs) and the presence of hypproteinemina have been reported to be associated with AAD [26,27], and are significantly correlated with the recurrence of C. difficile colitis. In the present study, the associations between AAD and the use of PPIs and serum albumin levels were not assessed but should be investigated in future studies. Also, human albumin may have been infused in some patients prior to admission to the ICU. Prospective studies are also needed to further clarify the relationship between albumin levels and PPIs and the development of AAD.

Critically ill patients who are fasting usually have intestinal dysfunction, which when combined with the use of antibiotics may cause an imbalance in the intestinal flora, promoting the occurrence of AAD. However, this study did not show an association between fasting (loss of appetite) and AAD. Further studies on the association between the length of the fasting time, antibiotic treatment, and AAD are needed. Patients with chronic underlying diseases and multiple organ dysfunction, who are on antibiotic treatment may be more prone to AAD [7,28].
This study showed that the incidence of AAD in critically ill patients with hypertension who were treated with enzyme inhibitor antibiotics was increased when compared with patients without hypertension. However, although univariate regression analysis showed that hypertension was associated with AAD, no correlation was found in multivariate regression analysis.

Previously published studies have shown that increased age is a risk factor for AAD [7,28,29], with older patients being more prone to AAD [2,17]. This study also found that the average age of critically ill patients with AAD was higher than that of patients without AAD. Although univariate regression analysis showed that increased age was associated with AAD, multivariate regression analysis did not show any correlation.

There have been previous studies that have shown that admission to hospital for more than two weeks is correlated with the occurrence of AAD [9,10]. In this study, when compared with patients with combined antibiotic treatment, the duration of stay in the ICU was found to be significantly lower in the monotherapy group (19.00±11.49 days vs. 9.60±6.76 days) (P<0.001), indicating that the occurrence of AAD could prolong the duration of ICU stay for critically ill patients. However, there was no significant difference in mortality between the two groups, which is consistent with our previous study on risk factors associated with AAD in critically ill patients [1], but inconsistent with the findings of some other studies.

The study findings by our group may be influenced by cultural factors as, for example, in rural areas around Shaanxi, in China, many families request discharge home for critically ill patients when they are still alive. These patients are classified as cases of ‘automatic discharge’ in the health statistics data, and would not be identifiable from the hospital records as cases of survival or death, which might explain the differences in mortality associated with AAD reported in the literature [1].

Conclusions

The use of enzyme inhibitor antibiotics is associated with the occurrence of antibiotic-associated diarrhea (AAD) in critically ill patients, particularly for those patients who require long-term antibiotic therapy. Their combined use with antifungal agents, quinolones, and oxazolidinones increases the incidence of AAD in critically ill patients receiving enzyme inhibitor antibiotic therapy. Therefore, to prevent the occurrence of AAD in critically ill patients, antibiotics should be administered conservatively according to their established indications. Combined antibiotic therapy and long-term antibiotic therapy should be avoided if possible. It is hoped that the findings from this study will provide a valuable basis for future prospective, large-scale, controlled, multinational studies to provide an evidence base for the rational use of antibiotics in critically ill patients and to reduce the occurrence of AAD.

References:

1. Litao G, Jingjing S, Yu L et al: Risk factors for antibiotic-associated diarrhea in critically ill patients. Med Sci Monit, 2018; 24: 5000–7
2. Huang H, Wu S, Wang M et al: Molecular and clinical characteristics of *Clostridium difficile* infection in a university hospital in Shanghai, China. Clin Infect Dis, 2008; 47(12): 1606–8
3. Tian CF, Su BY, Li YJ et al: Management of antibiotic-associated pseudo-membranous colitis in non-hospitalized and hospitalized patients. Pak J Pharm Sci, 2016; 29(5(Suppl.)): 1805–10
4. Ananthakrishnan AN: *Clostridium difficile* infection: Epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol, 2011; 8(1): 17–26
5. Surawicz CM, Brandt LJ, Binion DG et al: Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. Am J Gastroenterol, 2013; 108(4): 478–98
6. Blaabjerg S, Artzi DM, Aabenhus R: Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – a systematic review and meta-analysis. Antibiotics, 2017; 6(4): 21–37
7. Shen NT, Maw A, Tmanova LL et al: Timely use of probiotics in hospitalized patients with Clostridium difficile infection. J Hosp Infect, 2011; 78(3): 211–7
8. Kelly CP: A 76-year-old man with recurrent *Clostridium difficile*-associated diarrhea: Review of *Clostridium difficile* infection. J Clin Gastroenterol, 2010; 44(10): 911–22
9. Wilcox M, Minton J: Role of antibody response in outcome of antibiotic-associated diarrhea. Med Sci Monit, 2002; 8(3): BR85–88
10. Yoldas O, Altindis M, Cufali D et al: A diagnostic algorithm for the detection of *Clostridium difficile*-associated diarrhea. Balkan Med J, 2016; 33(1): 80–86
11. Lau CS, Chamberlain RS: Probiotics are effective at preventing *Clostridium difficile*-associated diarrhea: A systematic review and meta-analysis. Int J Med Sci, 2016; 9: 27–37
12. Roberts T, Kokai-Kun JF, Coughlin O et al: Tolerability and pharmacokinetics of SYN-004, an orally administered β-lactamase for the prevention of *Clostridium difficile*-associated disease and antibiotic-associated diarrhea, in two phase 1 studies. Clin Drug Invest, 2016; 36(9): 725–34
13. Leal JR, Heitman SJ, Conly JM: Cost-effectiveness analysis of the use of probiotics for the prevention of *Clostridium difficile*-associated diarrhea in a provincial healthcare system. Infect Control Hosp Epidemiol, 2016; 37(9): 1079–86
14. Ptich H, Braak NVD, Belkum AV et al: Characterization of *Clostridium perfringens* strains isolated from Polish patients with suspected antibiotic-associated diarrhea. Med Sci Monit, 2002; 8(3): BR85–88
15. Dubberke ER, Reske KA, Olsen MA et al: Evaluation of *Clostridium difficile*-associated disease as a risk factor for C difficile-associated disease. Arch Intern Med, 2007; 167(10): 1092–97
16. Wilcox M, Minton J: Role of antibody response in outcome of antibiotic-associated diarrhea. Lancet, 2001; 357(9251): 158–59
17. Viswanathan VK, Mallozzi MJ, Vedantam G: *Clostridium difficile* infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes. 2010; 1(4): 234–42
18. Can M, Beşirbellioglu BA, Avci IY et al: Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med Sci Monit, 2006; 12(4): P119–22
22. Owens RC, Donskey CJ, Gaynes RP et al: Antimicrobial-associated risk factors for *Clostridium difficile* infection. Clin Infect Dis, 2008; 46(1): S19–31

23. Pereira AS, Andrade SS, Monteiro J et al: Evaluation of the susceptibility profiles, genetic similarity and presence of QNR gene in *Escherichia coli* resistant to ciprofloxacin isolated in Brazilian hospitals. Braz J Infect Dis, 2007; 11(1): 40–43

24. Masuda N, Sakagawa E, Ohya S et al: Hypersusceptibility of the *Pseudomonas aeruginosa* NFXB mutant to beta-lactams due to reduced expression of the Amp C beta-lactamase. Antimicrob Agents Chemother, 2001; 45(4): 1284–86

25. Lee SH, Jeong SH, Park YM: Characterization of *blaCMY-10*, a novel plasmid-encoded Amp C type beta-lactamases gene in a clinical isolate of *Enterobacter aerogens*. J Appl Microbiol, 2003; 44(10): 744–52

26. Howell MD, Novack V, Grgurich P et al: Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. Arch Intern Med, 2010; 170(9): 784–90

27. Rotramel A, Poritz LS, Messaris E et al: PPI therapy and albumin are better predictors of recurrent *Clostridium difficile* colitis than choice of antibiotics. Gastrointest Surg, 2012; 16: 2267–73

28. Evans CT, Safdar N: Current trends in the epidemiology and outcomes of *Clostridium difficile* infection. Clin Infect Dis, 2015; 60(Suppl. 2): 566–71

29. Giannelli FR: Antibiotic-associated diarrhea. JAAPA, 2017; 30(10): 46–47

26. Howell MD, Novack V, Grgurich P et al: Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. Arch Intern Med, 2010; 170(9): 784–90

27. Rotramel A, Poritz LS, Messaris E et al: PPI therapy and albumin are better predictors of recurrent *Clostridium difficile* colitis than choice of antibiotics. Gastrointest Surg, 2012; 16: 2267–73

28. Evans CT, Safdar N: Current trends in the epidemiology and outcomes of *Clostridium difficile* infection. Clin Infect Dis, 2015; 60(Suppl. 2): 566–71

29. Giannelli FR: Antibiotic-associated diarrhea. JAAPA, 2017; 30(10): 46–47